Targeted therapy combined with chemoradiotherapy for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a diagnosis of squamous cell carcinoma of the cervix, at a stage that may be treated with radiation and chemo (stage IB3 to IVA).
- You have not had prior surgery, radiation, chemotherapy, or targeted therapy for cervical cancer.
- You are generally healthy, with no major heart, lung, liver, kidney, or blood problems.
- You are able to care for yourself (ECOG score 0-1).
- If you could become pregnant, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) alongside radiation therapy for people whose cervical cancer has returned or spread to a few other places. The goal is to see if this approach can help control the cancer better and improve survival.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
This trial tests a targeted drug (nimotuzumab) combined with radiation therapy for older adults with cervical cancer. The goal is to improve treatment outcomes for those who cannot tolerate chemotherapy.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.